An Aus­tralian man has been on a two-year-long quest to save his dog from can­cer.

Rosie, an 8-year-old Stafford­shire bull ter­ri­er mix who has a com­mon type of skin can­cer, has be­come an un­wit­ting celebri­ty in the AI world over the past few weeks.

Her own­er, Paul Conyn­g­ham, has found him­self on the me­dia cir­cuit, along­side Rosie, shar­ing how he used AI chat­bots like Ope­nAI’s Chat­G­PT and X’s Grok to de­vel­op a cus­tom mR­NA can­cer treat­ment for her. The saga caught the at­ten­tion of Ope­nAI CEO Sam Alt­man, who met with Conyn­g­ham and called it the “coolest meet­ing” of his week, sug­gest­ing “this should be a com­pa­ny.”

Pres­i­dent Don­ald Trump is re­port­ed­ly set to im­ple­ment 100% phar­ma­ceu­ti­cal tar­iffs as soon as Thurs­day, but ac­cord­ing to a draft seen by End­points News, it ap­pears they would on­ly af­fect a small por­tion of drug­mak­ers.

The draft doc­u­ment lays out how Trump is plan­ning to im­ple­ment the tar­iffs on the phar­ma in­dus­try and how drug­mak­ers with “most fa­vored na­tion” deals with the White House will be ex­empt un­til 2029.

While the White House did not im­me­di­ate­ly re­spond to ques­tions from End­points, Bloomberg News re­port­ed some de­tails of the plan Wednes­day, in­clud­ing that they could be an­nounced as soon as to­day. The draft doc­u­ment could still be sub­ject to change be­fore the ad­min­is­tra­tion of­fi­cial­ly an­nounces it.

A day af­ter Eli Lil­ly gained FDA ap­proval for its obe­si­ty pill Foun­dayo, No­vo Nordisk is fight­ing back with an analy­sis that it says shows the su­pe­ri­or­i­ty of its own oral drug.

The Dan­ish drug­mak­er's claims — it says its We­govy pill pro­duces rough­ly 3% greater weight loss than Foun­dayo — pre­view what's cer­tain to be a long-run­ning com­pe­ti­tion be­tween the com­pa­nies as they make sci­en­tif­ic claims and com­pete on price.

For now, No­vo would­n't con­firm or de­ny whether it in­tends to run a head-to-head study of the two pills — the gold stan­dard for any claim of su­pe­ri­or­i­ty. What No­vo has done is crunched num­bers from the main Phase 3 tri­als of the two prod­ucts — Lil­ly's AT­TAIN-1 study of Foun­dayo and its own OA­SIS-4 tri­al of the We­govy pill.